Human immunodeficiency virus in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 169-178

  Blumberg, E A ^a   Rogers, C C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

drug interaction; Drug resistance; highly active antiretroviral therapy; human immunodeficiency virus; reverse transcriptase inhibitor; viral load

Indexed keywords

ATAZANAVIR; ATOVAQUONE; AZATHIOPRINE; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DIDANOSINE; ENFUVIRTIDE; ETHAMBUTOL; FLUCONAZOLE; FOLINIC ACID; GANCICLOVIR; INTERFERON; ISONIAZID; ITRACONAZOLE; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PYRIMETHAMINE; RAPAMYCIN; RIFABUTIN; STAVUDINE; SULFADIAZINE; TACROLIMUS; TENOFOVIR; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALGANCICLOVIR;

ANEMIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; GRAFT SURVIVAL; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFLUENZA VACCINATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIA; TOXOPLASMOSIS; TUBERCULOSIS; VACCINATION; VIREMIA; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874846175     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12109     Document Type: Article

References (64)

1. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24: 697-706.
2. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
3. Kemmer NM, Sherman KE,. Liver transplantation trends in the HIV population. Digest Dis Sci 2011; 56: 3393-3398.
4. Simonds RJ, Holmberg SD, Hurwitz RL, et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992; 326: 726-732.
5. Ison MG, Llata E, Conover CS, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11: 1218-1225.
6. Villa E, Nanni Costa A,. HIV-positive organs used for transplant in Italy due to human error. Euro Surveillance: Eur Commun Dis Bull 2007; 12: E070308 1.
7. HIV transmitted from a living organ donor-New York City, 2009. MMWR Morbid Mort Week Rep 2011; 60: 297-301.
8. Phair J, Palella F,. Renal disease in HIV-infected individuals. Curr Opin HIV AIDS 2011; 6: 285-289.
9. Sherman KE, Thomas DL, Chung RT,. Human immunodeficiency virus and liver disease forum 2010: Conference proceedings. Hepatology 2011; 54: 2245-2253.
10. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. New Engl J Med 2003; 348: 2323-2328.
11. Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant 2009; 28: 667-669.
12. Grossi PA BE,. Human immunodeficiency virus and hepatitis C virus in cardiothoracic transplantation and mechanical circulatory support. In:, Mooney ML HM, Husain S, Kirklin JK, eds. Diagnosis and management of infectious diseases in cardiothoracic transplantation and mechanical circulatory support. Philadelphia: Elsevier, 2011, pp. 269-280.
13. Castel MA, Perez-Villa F, Miro JM,. Heart transplantation in HIV-infected patients: More cases in Europe. J Heart Lung Transplant 2011; 30: 1418.
14. Grossi PA, Righi E, Gasperina DD, et al. Report of four simultaneous pancreas-kidney transplants in HIV-positive recipients with favorable outcomes. Am J Transplant 2012; 12: 1039-1045.
15. Akhtar MZ, Patel N, Devaney A, et al. Simultaneous pancreas kidney transplantation in the HIV-positive patient. Transplant Proc 2011; 43: 3903-3904.
16. Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH, Jr., Human immunodeficiency virus infection in patients with solid-organ transplants: Report of five cases and review. Rev Infect Dis 1991; 13: 537-547.
17. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL,. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 1633-1639.
18. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004-2014.
19. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: The Paris experience. Am J Transplant 2010; 10: 2263-2269.
20. Mazuecos A, Fernandez A, Andres A, et al. HIV infection and renal transplantation. Nephrol, Dialysis, Transplant 2011; 26: 1401-1407.
21. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 1622-1629.
22. Kumar MSA KS, Ranganna K, Malat GE, Kumar AMS, Jacobson JM, In HIV+ patients with end stage renal disease (ESRD) kidney transplantation significantly prolongs long-term patient survival compared to chronic dialysis treatment. Am J Transplant 2008; 8: S179.
23. Mindikoglu AL, Regev A, Magder LS,. Impact of human immunodeficiency virus on survival after liver transplantation: Analysis of United Network for Organ Sharing database. Transplantation 2008; 85: 359-368.
24. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
25. Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: A systematic review and meta-analysis with synthetic cohort. AIDS 2011; 25: 777-786.
26. Antonini TM, Sebagh M, Roque-Afonso AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011; 11: 1686-1695.
27. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10: 1268-1275.
28. Baccarani U, Adani GL, Bragantini F, et al. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc 2011; 43: 1119-1122.
29. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study. Am J Transplant 2012; 12: 1866-1876.
30. de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993.
31. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ,. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 1425-1430.
32. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138: 159-164.
33. Ragni MV DM, Roland ME, Wong, M, et al. Outcomes of liver transplantation in HIV-infected hemophilic candidates. Hemophilia 2012; in press.
34. Locke JE, Montgomery RA, Warren DS, Subramanian A, Segev DL,. Renal transplant in HIV-positive patients: Long-term outcomes and risk factors for graft loss. Arch Surg 2009; 144: 83-86.
35. Bhagat V, Foont JA, Schiff ER, Regev A,. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl 2008; 14: 92-95.
36. Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: A FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18: 70-81.
37. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355-365.
38. Gasser O, Bihl F, Sanghavi S, et al. Treatment-dependent loss of polyfunctional CD8 +T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation. Am J Transplant 2009; 9: 794-803.
39. Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG,. Thymoglobulin-associated Cd4 +T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6: 753-760.
40. Nissen NN, Barin B, Stock PG,. Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol 2012.
41. Vibert E, Duclos-Vallee JC, Ghigna MR, et al. Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection. Hepatology 2011; 53: 475-482.
42. Cherian PT, Alrabih W, Douiri A, et al. Liver transplantation in human immunodeficiency virus-infected patients: Procoagulant, but is antithrombotic prophylaxis required? Liver Transpl 2012; 18: 82-88.
43. Esposito L, Kamar N, Tkaczuk J, Abbal M, Durand D, Rostaing L,. Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients. Transplant Proc 2005; 37: 785-787.
44. Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31: 45-49.
45. Donia M, McCubrey JA, Bendtzen K, Nicoletti F,. Potential use of rapamycin in HIV infection. Br J Clin Pharmacol 2010; 70: 784-793.
46. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820.
47. Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V,. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundment Clin Pharmacol 2009; 23: 423-425.
48. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941-952.
49. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-944.
50. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-1952.
51. Meeting materials for the May 11, 2012 meeting of the Antiviral Drugs Advisory Committee Meeting. 2012 (Accessed October 1, 2012, at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM303397.pdf).
52. Li J, Chen G, Ye P, et al. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J Immunol 2011; 186: 3753-3761.
53. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG,. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12: 801-807.
54. Bani-Sadr F, Palmer P, Scieux C, Molina JM,. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39: 1062-1064.
55. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H,. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207; quiz CE1-4.
56. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: End of treatment (week 48) interim results. J Hepatology 2012; 56 (Suppl 2): S22.
57. Dieterich D SV, Soriano V, Sherman K, et al. Telaprevir in Combination with pegylated interferon-alfa-2a + Ribavirin in HCV/HIV-coinfected patients: A 24-week treatment interim analysis. In: Proceeding of the 19th Conference on Retroviruses and Opportunistic Infections; 2012 Seattle, WA. Abstract 46.
58. Klein R, Struble K., Victrelis (Boceprevir) label change reflects drug-drug interaction information with hiv protease inhibitors; http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm314055.htm. Accessed September 1, 2012.
59. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417.
60. Wojcik K, Vogel M, Voigt E, et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: Outcome in the Bonn cohort. AIDS 2007; 21: 1363-1365.
61. Castells L, Esteban JI, Bilbao I, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antiviral Ther 2006; 11: 1061-1070.
62. Rogers CC SD, Kim M, et al. Telaprevir can be safely used with tacrolimus in the post-transplant setting. Am J Transplant 2012; 12: 431 (abstract 1372).
63. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hcv protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012.
64. Muller E, Kahn D, Mendelson M,. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010; 362: 2336-2337.